Additionally, there were no obvious difference in the concentrations of chemokines CXCL13 [193.43 (151.22, 228.43) vs. 184.19 (134.93, 224.37), P = 0.381], CXCL10 [452.52 (376.24, 540.13) vs. 425.73 (374.39, 570.54), P = 0.749], CX3CL1 [3.08 (2.42, 3.79) vs. 3.05 (2.57, 3.75), P = 0.965], CCL2 [357.08 (294.46, 447.02) vs. 360.52 (318.30, 433.48), P = 0.988] between ALS patients and controls. This evidence concerns the gene CCL2 and amyotrophic lateral sclerosis.